NCT03895970View on ClinicalTrials.gov

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 20, 2019

Primary Completion Date

April 1, 2021

Study Completion Date

August 1, 2021

Conditions
Liver Neoplasm Malignant PrimaryCholangiocarcinomaCombinational ImmunotherapyBiomarker
Interventions
DRUG

Lenvatinib plus Pembrolizumab

Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT03895970 - Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors | Biotech Hunter | Biotech Hunter